Lotus Pharmaceutical (TPE:1795) completed registration of its capital reduction following the redemption of RSA shares, after approval from Taiwan's Ministry of Economic Affairs on Aug. 31, according to a Thursday filing.
Paid-in capital fell to NT$2.667 billion from NT$2.669 billion, while shares outstanding dropped to 262.7 million from 262.8 million, excluding 4 million treasury shares.